header("Access-Control-Allow-Origin: *"); ?>
therapeuticpublished patents
oncologypublished patents
research tools
diagnosticpublished patents
Welcome to our Technology Offers website You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.
Diagnostic
Research
Therapeutic
Flow Cytometry
Immunocytochemistry
Immunoprecipitation
In vivo studies
Western Blot
Cardiovascular Diseases
Central Nervous System
Dermatology
Ear nose throat disease
Gastrointestinal Diseases
Genetic Disorders
Genito Urinary System
Hematological Disorders
Immunology
Musculoskeletal
Nutritional disorder
Oncology
Ophtalmology
Respiratory Disease
Women health
Others
Infectious diseases
In this study, the Inventors report that CD9 is a key component of PC-associated CAFsderived ANXA6+-EVs. They determined that CD9 is expressed by […]
T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, […]
Inventors analyzed the prognostic value of tumor and stromal-derived SPARC in a large series that included 148 non-metastatic TNBC patients with a […]
The invention is in the field of therapy of antibody deficiencies such as immune diseases and inflammatory disorders. The inventors demonstrate for […]
The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) […]
The inventors have surprisingly demonstrated that GD3 positive senescent cells inhibit NK cell in vitro and in vivo while GD3 negative senescent cells […]
Inventor's general objective was to investigate the potential role of mucosal thrombin in intestinal inflammation and its mechanisms of action. […]
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, […]
The severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR. Lipocalin 2 (Lcn2, […]
The present invention relates to a PAK-1 and/or PAK-2 inhibitor for use in the treatment of NLRP3 inflammasome mediated IL-1beta dependent disorders […]
Here the inventors show, using in vivo imaging and viral approaches, that calcium released by […]
In the present invention it is shown that the inactivation of the Pyk2 gene does not alter […]
In the present invention it is shows that the inactivation of the Pyk2 gene does not alter […]
The present invention relates to a method for treating a subject suffering from a cancer comprising […]
HSP110 is involved in multiple tumorigenic processes, but no inhibitor was known to date. The […]
Anthracyclines such as doxorubicin are chemotherapeutic molecules are also widely incorporated in […]
The present invention relates to the treatment of idiopathic pulmonary fibrosis. Today, there is no […]
The present invention relates to methods and pharmaceutical compositions for the treatment of […]
Heart failure with preserved ejection fraction (HFpEF) which results from diastolic dysfunction is a […]
Inventors have surprisingly found that Emricasan is a much more potent inhibitor of monocyte […]
The present invention relates to a genetically modified hematopoietic stem cell (HSC) comprising, […]
The growing prevalence of obesity and type 2 diabetes complicates risk and clinical management by […]
Research tool licensing team
researchtools@inserm-transfert.fr
User accounts are momentarily unavailable
The Inserm Transfert website is currently undergoing maintenance. It will be available again in a few hours.